MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, RNAC made $78K in revenue. -$39,189K in net income. Net profit margin of -50242.31%.

Income Overview

Revenue
$78K
Net Income
-$39,189K
Net Profit Margin
-50242.31%
EPS
-$1.46
Unit: Thousand (K) dollars
Revenue Breakdown
    • Grant
Revenue Breakdown
    • Other expense (income), net
    • Research and development-Descart...
    • General and administrative
    • Others

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Total revenues
78 947 452 298
Research and development
19,463 14,689 13,802 14,869
General and administrative
7,114 8,197 7,716 7,240
Impairment of indefinite-lived intangible and long-lived assets
-56,700 --
Total operating expenses
26,577 79,586 21,518 22,109
Operating loss
-26,499 -78,639 -21,066 -21,811
Interest income
--1,548 1,748
Loss on change in fair value of forward contract liabilities
-0* 0 0
Interest income
1,026 1,645* --
Gain on change in fair value of warrant liabilities
-94 -707 -516 -654
(loss) gain on change in fair value of contingent value right liability
13,800 23,100 16,900 -35,300
Other expense, net
-3 4,513* 0 -5
Total other (expense) income, net
-12,683 -16,235 --
Loss before income taxes
--94,874* --
Income tax benefit (expense)
--2,298* --
Net loss
-39,182 -92,576 -35,902 15,886
Foreign currency translation adjustment
-7 11 -10 12
Total comprehensive loss
-39,189 -92,565 -35,912 15,898
Basic EPS
-1.46 -3.559 -1.38 0.51
Diluted EPS
-1.46 -3.624 -1.38 0.5
Basic Average Shares
26,855,158 26,007,512 26,002,892 25,980,262
Diluted Average Shares
26,855,158 25,540,523 26,002,892 26,447,251
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Total comprehensiveloss-$39,189K (-121.68%↓ Y/Y)Net loss-$39,182K (-121.24%↓ Y/Y)Foreign currencytranslation adjustment-$7K (-121.88%↓ Y/Y)Grant$78K (-88.86%↓ Y/Y)Operating loss-$26,499K (-21.06%↓ Y/Y)Total other (expense)income, net-$12,683K Total revenues$78K (-92.91%↓ Y/Y)Interest income$1,026K (-49.08%↓ Y/Y)Gain on change in fairvalue of warrant...-$94K (94.83%↑ Y/Y)Total operatingexpenses$26,577K (15.61%↑ Y/Y)(loss) gain on change infair value of...$13,800K (4088.44%↑ Y/Y)Other expense, net-$3K Research and development$19,463K (32.64%↑ Y/Y)General andadministrative$7,114K (-14.44%↓ Y/Y)

Cartesian Therapeutics, Inc. (RNAC)

Cartesian Therapeutics, Inc. (RNAC)